Discover why LeMaitre's expansion in the peripheral vascular disease market and strong dividend growth make it an appealing ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $95.25, a high ...

Lemaitre Vascular ( (LMAT) ) has released its Q3 earnings. Here is a breakdown of the information Lemaitre Vascular presented to its investors.

LeMaitre Vascular Inc (LMAT) reports a strong Q3 with 16% sales growth, 49% EPS increase, and strategic market expansion ...

Lemaitre Vascular (LMAT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Daniel ...

LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.33 per share a year ago. These ...

Third Quarter 2024 Results Key Financial Results Revenue: US$54.8m (up 16% from ...

Welcome to the LeMaitre Vascular Q3 2024 Financial Results Conference Call. As a reminder, today's call is being recorded. At this time, I would like to turn the call over to Mr. J.J. Pellegrino ...

Friday saw an update from Stifel on LeMaitre Vascular (NASDAQ:LMAT) shares, with the firm raising the price target on the company's shares to $100 from $95, while maintaining a Buy rating.

For the current quarter ending in December, LeMaitre said it expects revenue in the range of $54.9 million to $56.9 million. The company expects full-year earnings to be $1.91 to $1.96 per share, with ...

LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.33 per share a year ago.